Clin Pediatr: Should blood test monitoring be performed on patients who have been receiving preventive treatment for TMP-SMZ for a long time?

Blood test monitoring is a common practice in patients who have been receiving prevention treatment for TMP-SMZ for a long time to prevent recurrent urinary tract infections.
the multi-center, randomized, placebo-controlled trial recruited 607 children between the ages of 2 and 71 months who were diagnosed with bladder urethra reflow after a symptomatic urinary tract infection.
study participants received TMP-SMZ (n s 302) or placebo (n s 305) and followed it for 2 years.
results, serum electrolytes (n≥370), creatinine (n- 310) and whole blood cell counts (n≥206) were measured at the beginning of the study and at the end of the 24-month study.
no significant electrolyte, kidney or hematological abnormalities were found in the treatment and placebo groups.
study observed changes in several laboratory parameters in the treatment and placebo groups, which are usually expected of physiological maturity.
changes within the normal age range.
long-term use of TMP-SMX had no effect on whole blood cell count, serum electrolytes, or creatinine.
, the findings do not support routine monitoring of these laboratory tests in children who have been receiving TMP-SMZ preventive treatment for a long time.
.